← Back

Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Price · split & dividend adjusted
News & notes moving LITS
Digital Finance & Tokenization

Lite Strategy to Join Panel at Litecoin Foundation Summit in Amsterdam

Lite Strategy, the first U.S. public company to adopt Litecoin as its primary treasury reserve asset, will participate in a featured panel at the Litecoin Foundation Summit in Amsterdam on June 22, 2026. The panel, titled "Litecoin's institutional opportunity," will include Lite Strategy board members Charlie Lee, creator of Litecoin, and Joshua Riezman, Chief Strategy Officer and Head of U.S. Legal at GSR, with moderation by digital asset educator Randi Hipper. This marks the first appearance of a NASDAQ-listed digital asset treasury company at the annual summit. The event comes as Litecoin draws institutional attention following the SEC's March 2026 guidance classifying LTC as a digital commodity, the October 2025 launch of the Canary spot Litecoin ETF on Nasdaq, and Lite Strategy's own formation as an active Litecoin treasury company.
GlobeNewswire·69dRead more ▾